The CONTAIN (CiclesOnide cliNical TriAl covId-19 treatmeNt) is a randomized control study of
ciclesonide vs placebo for mild covid-19 disease. The need for potential therapy for COVID-19
patients is urgent. Ciclesonide has shown encouraging in vitro results, is easy to be used
and is readily available. It has a low rate of side effects and few interactions with other
drugs. It is unusual to use an inhaled steroid drug for COVID-19 but there has been new data
suggesting steroids may have an antiviral effect in addition to an anti-inflammatory effect.
Investigators propose to use inhaled and nasal ciclesonide to stop viral replication in the
nose and airways. Investigators hope this will accelerate recovery from COVID-19 illness in
individuals who are not admitted to hospital at time of diagnosis of COVID-19.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
McGill University Health Centre/Research Institute of the McGill University Health Centre